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The mammalian target of rapamycin (mTOR) pathway
is a central pathway that regulates mRNA translation,
protein synthesis, glucose metabolism, lipid synthesis
and autophagy, and is involved in malignant
transformation. Several randomized trials have shown
that the use of mTOR inhibitors could improve patient
outcome with hormone receptor-positive or human
epidermal growth factor receptor-2-positive breast
cancer. This review analyzes new perspectives from
these trials. Preclinical studies have suggested that
the mTOR pathway may play a role in the resistance
to hormone therapy, trastuzumab and chemotherapy
for breast cancer. This concept has been tested in clinical
trials for neoadjuvant treatment and for metastatic
breast cancer patients. Also, much effort has gone into
the identification of biomarkers that will allow for more
precise stratification of patients. Findings from these
studies will provide indispensable tools for the design
of future clinical trials and identify new perspectives and
challenges for researchers and clinicians.phorylate TSC2 [4] or directly phosphorylates RAPTORThe mammalian target of rapamycin pathway
As a serine/threonine kinase and downstream member
of the phosphatidylinositol-3-kinase (PI3K)/protein
kinase B (AKT) and adenosine monophosphate-activated
protein kinase (AMPK) pathways, mammalian target of
rapamycin (mTOR) is a key regulator of cell growth and
metabolism. In cells, mTOR is a component of two struc-
turally similar complexes, mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2). Both complexes contain
mTOR, the DEP-domain containing mTOR interacting
protein and mLST8 (mTOR associated protein); mTORC1* Correspondence: fabrice.andre@gustaveroussy.fr
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© 2014 BioMed Central Ltd.also includes the regulatory associated protein of mTOR
(RAPTOR) and a 40 kDa proline-rich AKT substrate,
while mTORC2 contains the rapamycin insensitive com-
panion of mTOR (RICTOR), the mammalian stress acti-
vated map kinase interacting protein 1 and protein
observed with RICTOR.
The mTOR complexes are functionally distinct. mTORC1
promotes mRNA translation and protein synthesis by
phosphorylation of ribosomal protein S6 kinase (S6K1)
and eIF4E binding protein 1 (4E-BP1), and inhibits au-
tophagy. Moreover, mTORC1 has roles in glucose meta-
bolism, lipid synthesis and can phosphorylate the estrogen
receptor (ER) via S6K1 [1]. mTORC2 organizes the cellular
actin cytoskeleton and regulates AKT phosphorylation [2].
For full activation AKT requires phosphorylation by PI3K
(threonine 308) and mTORC2 (serine 473) (Figure 1).
mTOR can be activated by the PI3K-dependent pathway
though AKT activation and dual inhibition of tuberous
sclerosis 1/2 (TSC1/2) and Ras homolog enriched in brain
(Rheb) and can be regulated by the AMPK-dependant en-
ergy pathway [3] (Figure 2). Indeed, AMPK activated by
the liver kinase B1 (LKB1) tumor suppressor can phos-
in order to inhibit mTORC1 [5].
Interestingly, a large panel of activating mutations is
found in the mTOR pathway, including PI3KCA (the
PI3K catalytic subunit alpha isoform), AKT1 and mTOR
mutations, as well as PTEN loss. Drugs targeting various
levels of the mTOR pathway have been developed, in-
cluding PI3K, AKT and mTOR inhibitors. mTORC1 is
the biological target for rapalogs such as everolimus and
temsirolimus, whereas other inhibitors are capable of
simultaneously targeting both mTOR complexes.Clinical development of rapalogs in breast cancer
Estrogen receptor-positive breast cancer
Endocrine manipulation is the principal treatment for
ER + breast cancer patients, both in the early and ad-
vanced phases of the disease. However, not all patients
with ER + tumors are sensitive to endocrine treatment
Figure 1 mTOR pathway and actions. Schematic representation of the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mammalian
target of rapamycin (mTOR) pathway. mTOR complex (mTORC)1 is involved in mRNA translation and protein synthesis, glucose metabolism, lipid
synthesis, and estrogen receptor (ER) phosphorylation and inhibits autophagy. mTORC2 functions in AKT phosphorylation on serine 473 and regulates
the cellular actin cytoskeleton. 4E-BP1, eIF4E binding protein 1; AMPK, adenosine monophosphate-activated protein kinase; E, Estrogen; LKB1, liver kinase
B1; MEK, mitogen activated protein kinase/extracellular signal regulated kinase; P, phosphorylated; raf, rat fibrosarcoma virus; Ras, rat sarcoma virus; S6K1,
ribosomal protein S6 kinase; TSC1/2, tuberous sclerosis 1/2.
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tive patients may develop a secondary resistance during
or after treatment. Multiple mechanisms of resistance to
anti-endocrine agents have been described. mTOR acti-
vation was shown to mediate resistance to endocrine
therapy in preclinical models [6]. Furthermore, mTOR
inhibitors such as everolimus synergized with letrozole
in preclinical models [7] and mTOR was described as a
mechanism facilitating escape of long-term estrogen
deprivation [8]. The addition of mTOR inhibitors to
endocrine treatment has been investigated in phase II
and III studies, including patients with hormone
receptor-positive (HR+) and human epidermal growth
factor receptor-2-negative (HER2-) breast cancer. Three
major randomized trials have reported consistent data
on everolimus efficacy in ER + breast cancer. In a ran-
domized phase II neoadjuvant trial including 270 pa-
tients, everolimus in addition to letrozole was compared
against letrozole plus placebo [9]. The clinical response
rate by palpation was higher in the everolimus arm (68
versus 59%, P = 0.06, prespecified cutoff for significance<0.1), suggesting everolimus increased letrozole efficacy
in the neoadjuvant setting [9]. Interestingly, Ki67 expres-
sion was evaluated at baseline and after 15 days of treat-
ment, in 91 tumors for the everolimus arm and 82
tumors for the placebo arm, and the evaluation was
based on the reduction in Ki67 expression to natural
logarithm of percentage positive Ki67 of less than 1 at
day 15. The results show a greater antiproliferative re-
sponse for the everolimus treated patients (57% of pa-
tients with everolimus responded versus 25% of patients
with placebo, P < 0.01). TAMRAD was a phase II ran-
domized trial of tamoxifen plus everolimus versus tam-
oxifen alone in patients with HR+, HER2- advanced
breast cancer and previous exposure to an aromatase in-
hibitor (AI) [10]. The primary end point was the clinical
benefit rate of tamoxifen plus everolimus and was esti-
mated as 61% (compared to 42% with tamoxifen alone).
Otherwise, time to progression appeared to be more
prolonged with the combination compared to tamoxifen
alone (8.6 months versus 4.5 months, hazard ratio 0.54,
95% CI 0.36 to 0.). At the last update of overall survival
Figure 2 mTOR-dependent pathways and inhibitors. Mammalian target of rapamycin (mTOR) depends on two pathways: the
phosphatidylinositol-3-kinase (PI3K)-dependent pathway and the 5′ adenosine monophosphate-activated protein kinase (AMPK)-dependent
pathway (the energy pathway). Various inhibitors have been reported to act on one kinase in each of the pathways. LKB1, liver kinase B1; mTORC,
mTOR complex; TSC1/2, tuberous sclerosis 1/2.
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combination group versus 31 with tamoxifen alone. Me-
dian overall survival was not available for the combi-
nation group while it was 32.9 months for tamoxifen
alone. The phase III trial BOLERO-2 enrolled 724 pa-
tients with HR + advanced breast cancer who experi-
enced a recurrence during or within 12 months after the
end of adjuvant non-steroidal aromatase inhibitor (nsAI)
treatment or progression during or within 1 month after
the end of nsAI treatment for advanced disease [11]. Pa-
tients were randomized to receive everolimus combined
with exemestane versus exemestane plus placebo. At the
time of the pre-planned interim analysis, the median
progression-free survival (PFS) was significantly better
for the everolimus plus exemestane arm compared to
the control arm, for both local investigator and central
assessment analyses (6.9 months versus 2.8 months, ha-
zard ratio 0.43, 95% CI 0.35 to 0.54, P < 0.001; 10.6 ver-
sus 4.1 months, hazard ratio 0.36, 95% CI 0.27 to 0.47,
P < 0.001) [11]. At a median follow-up of 18 months, the
addition of everolimus to exemestane was confirmed to
significantly improve patient outcome over exemestane
alone (median PFS 7.8 versus 3.2 months, hazard ratio
0.45, 95% CI 0.38 to 0.54, P < 0.0001) [12]. Everolimus
has since received approval from the Food and DrugAdministration and the European Medicines Agency in
combination with exemestane for HR+/HER2- advanced
breast cancer patients after failure of a nsAI [13,14].
However, many questions remain to be addressed. For
example, the role of everolimus in premenopausal
women and endocrine sensitive patients has yet to be
established. Other schedules, such as everolimus alone
or in combination with chemotherapy, need to be eva-
luated and compared to the approved treatments. On-
going trials are beginning to address some of these
issues. BOLERO-6 is a three-arm phase II randomized
trial comparing everolimus plus exemestane, exemestane
alone and capecitabine for patients with HR+/HER2-
advanced breast cancer refractory to nsAI (Clinical-
Trials.gov number NCT01783444), while BOLERO-4
(single-arm, phase II) is evaluating the combination of
everolimus and letrozole as a first-line treatment for
patients with ER + advanced breast cancer (endocrine
treatment for early breast cancer is allowed, if com-
pleted 1 year before enrollment) (ClinicalTrials.gov
number NCT01698918).
A broad clinical development program for everolimus
in early breast cancer is being pursued, with two
investigator-initiated studies evaluating everolimus in
the adjuvant setting in patients with high-risk disease.
Vicier et al. Breast Cancer Research 2014, 16:203 Page 4 of 9
http://breast-cancer-research.com/content/16/1/203An ongoing American study is planning to enroll up to
3,400 premenopausal and postmenopausal women with
HR+/HER2- breast cancer who have received prior stan-
dard neoadjuvant or adjuvant chemotherapy. Patients will
be randomized to receive everolimus 10 mg/day or pla-
cebo for the first year of 5 years of adjuvant endocrine
therapy (ClinicalTrials.gov number NCT01674140). A
phase III French-UK study will evaluate the addition of
everolimus to adjuvant endocrine treatment for patients
with HR+/HER2- breast cancer who remain disease-free
following 2 to 3 years of adjuvant endocrine therapy
(ClinicalTrials.gov number NCT01805271). These studies
have a different design and will hopefully provide clarifi-
cations on two different points. The American one will
test the efficacy of adjuvant everolimus upfront for all
subjects; therefore, the biologic background refers
mainly to baseline mTOR activation. In contrast, the
European study plans the introduction of everolimus
after 2 to 3 years of adjuvant endocrine therapy, and
will mainly focus on the hypothesis of induced mTOR
activation occurring during anti-endocrine treatment.
The results are expected to shed light on the underlying
disease mechanisms.
Despite these interesting findings, one phase III ran-
domized trial appeared to be negative: the HORIZON
trial enrolled 1,112 AI naïve patients to evaluate the effi-
cacy and safety of a letrozole and temsirolimus combin-
ation daily versus letrozole and placebo in patients with
advanced HR + breast cancer. Unfortunately, HORIZON
was stopped for futility as the letrozole-temsirolimus
combination did not lead to an improvement in PFS,
which was the primary end point, and more grade 3 or 4
adverse events (AEs) were noticed (median PFS of
9 months, hazard ratio 0.90, 95% CI 0.76 to 1.07, P =
0.25). This trial was especially conducted with AI naïve
patients and only 40% received adjuvant endocrine the-
rapy, testing the primary resistance and possibly explain-
ing the negative results compared to the BOLERO-2
trial [15].Human epidermal growth factor receptor-2-positive
breast cancer
HER2 overexpression/amplification leads to an aggres-
sive breast cancer phenotype and poor prognosis [16].
The introduction of the recombinant humanized anti-
HER2 monoclonal antibody trastuzumab in the manage-
ment of this breast cancer subtype has dramatically im-
proved patient outcome [17]. However, many patients
develop resistance to this therapy. PTEN loss or PI3K
mutation have been shown to induce mTOR activation
and mediate trastuzumab resistance [18]. Other precli-
nical studies have shown that rapalogs overcome resis-
tance to trastuzumab [19], suggesting that mTORinhibitors could potentially delay or reverse trastuzumab
resistance.
Early-phase trials (phase Ib-II) have evaluated the effi-
cacy of the addition of everolimus to trastuzumab plus
paclitaxel or vinorelbine for patients with HER2+ ad-
vanced breast cancer who progressed after trastuzumab.
These studies reported overall response rates in the
range of 19 to 44%, indicating that mTOR inhibitors can
overcome resistance to trastuzumab [20-22].
BOLERO-1 and BOLERO-3 are randomized phase III tri-
als addressing HER2+ advanced breast cancer. BOLERO-3
has tested the hypothesis that addition of everolimus could
overcome an acquired resistance to anti-HER2 therapy
[23]. Patients (n = 572) have been receiving vinorelbine,
trastuzumab with everolimus (5 mg/day) or placebo, and
initial results indicate that everolimus is able to improve
PFS in trastuzumab-resistant patients (hazard ratio 0.78,
0.95% CI 0.65 to 0.95). Interestingly, PFS subgroup analyses
determined more benefit for patients with prior adjuvant
or neoadjuvant trastuzumab treatment and who were
HR- (hazard ratio 0.65, 95% CI 0.48 to 0.87).
BOLERO-1 is an ongoing phase III randomized trial
involving patients with HER2+ advanced breast cancer
who have not received trastuzumab in the metastatic
setting, thus testing the potential for everolimus to over-
come baseline trastuzumab resistance. Patients will be
randomized to receive paclitaxel plus trastuzumab and
the same combination plus everolimus (10 mg/day). The
primary end point will be PFS (ClinicalTrials.gov num-
ber NCT00876395).
Considering the research efforts currently being ap-
plied to the development of HER2 drugs, it will be im-
portant to identify patients that are highly sensitive to
everolimus. Indeed, the results of BOLERO-3 should
have particular relevance for this issue.
Triple-negative breast cancer
The rationale for developing rapalogs for treatment of
triple-negative breast cancer (TNBC) is based on the re-
cent detection of a high frequency of PTEN loss, which
is known to correlate with AKT activation, in array com-
parative genomic hybridization studies [24,25]. A recent
gene expression analysis of TNBC identified at least six
tumor molecular subtypes, including a mesenchymal-
like subset that was highly sensitive to PI3K/mTOR
inhibitors in vitro and in vivo [26]. Additionally,
everolimus has been shown to sensitize basal-like
breast cancer to DNA damaging agents, including cis-
platinum [27,28]. These preclinical findings have led
to clinical evaluation of everolimus in TNBC. In a
phase II neoadjuvant study including 50 TNBC pa-
tients, everolimus has been tested in addition to 12
weekly administrations of paclitaxel followed by fluo-
rouracil, epirubicin and cyclophosphamide every
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sponse rate in the everolimus treatment compared to
chemotherapy alone (48% versus 30%), but this did not
reach statistical significance (P = 0.075). Another phase II
randomized study comparing neoadjuvant cisplatin and
paclitaxel with or without everolimus (Clinicaltrials.gov
number NCT00930930) is ongoing.
Critical points for future research will be to define, if
possible, a subgroup of TNBC patients most likely to
benefit from the addition of everolimus to chemotherapy
and to define the potential predictive role of PTEN loss.Chemosensitization
Preclinical studies have suggested that rapalogs could
synergize with taxanes [30] and this has been addressed in
a recent neoadjuvant phase III study [31]. Patients with
HER2- breast cancer (n = 403) were enrolled. Patients
showing no response after four cycles of preoperative epiru-
bicin and cyclophosphamide (with or without bevacizumab)
were randomized to receive paclitaxel or paclitaxel plus
everolimus (starting at 2.5 mg every other day and escalat-
ing to 5 mg per day). The pathologic complete response
was 3.6% in the paclitaxel group, compared with 5.6% in
the paclitaxel plus everolimus group (P = 0.476). Moreover,
the clinical response rate was 52% and 62% in the paclitaxel
alone and everolimus groups, respectively. Although there
is currently no evidence to suggest everolimus may be able
to overcome chemoresistance in these patients, the appro-
priateness of pathologic complete response as the optimal
end point for the efficacy of new targeted agents is ques-
tionable. Furthermore, everolimus and chemotherapy dose
intensities may require optimization for best results. Other
studies, such as a randomized phase II trial evaluating a
combination of paclitaxel and bevacizumab with or without
everolimus (10 mg/day) for patients with HER2- metastatic
breast cancer (Clinicaltrials.gov number NCT00915603) are
ongoing.Mammalian target of rapamycin inhibitor toxicities
In the everolimus trials, the most common AEs are fa-
tigue, stomatitis, anorexia, diarrhea, metabolic disorders
with hyperglycemia, noninfectious pneumonitis and
hematologic disorders. These AEs were noticed in the
TAMRAD study, mostly grade 1 to 2 in severity [10], as
well as in the BOLERO-2 trial, in which 23% of patients
in the combination treatment had serious AEs versus
12% in the exemestane group [9]. In a phase 1 study, sto-
matitis was the most common AE, occurring in 27 of the
33 patients enrolled at any grade, 7 of which were grade
3 [21]. They also observed one interstitial pneumonitis.
Everolimus is usually relatively tolerated but sometimes
needs to be adapted with dose reduction and a perfect
knowledge of AEs is required for treating patients.Similar AEs were observed in the temsirolimus trial, with
some cases of headache and fever; most grade 3 AEs were
hyperglycemia, hyperlipemia, dyspnea and asthenia [15].Moving beyond rapalogs: how to prepare second
generation trials?
Biomarkers for patient stratification
Three principal questions remain to be addressed in bio-
marker research into mTOR inhibitors. Firstly, it will be
important to define whether mTOR ‘activated’ tumors
are more sensitive to rapalogs. To achieve this, it will be
necessary to identify biomarkers of mTOR pathway acti-
vation and evaluate the sensitivity of the mTOR acti-
vated breast cancer population to mTOR inhibition.
4EBP1 is phosphorylated by mTOR into p4EBP1, which
is a downstream effector of the mTOR pathway
(Figure 3). Biomarker studies conducted on 55 sam-
ples from the TAMRAD trial suggested that everoli-
mus is more effective for patients with high levels of
p4EBP1, suggesting that baseline mTOR activation is
associated with sensitivity to everolimus [32].
Secondly, it will be important to identify patients that
are hypersensitive to mTOR inhibitors. Analysis of such
a subgroup could lead to the identification of genetic
drivers of mTOR-activation. GOLPH3 amplifications
and PTEN, STK11 and TSC1 mutations have all been
described as outlier responders to everolimus [33-36].
Sensitive patients can then be further classified on the
basis of the pathway responsible for everolimus efficacy
(for example, the PI3K-dependent ‘classic’ pathway or
the LKB1/AMPK metabolic pathway). Preclinical find-
ings suggest that PI3K mutation is a predictor of mTOR
inhibition efficacy [37]; however, recent next-generation
sequencing results of 309 samples from the BOLERO-2
trial failed to confirm this. Indeed, neither PIK3CA mu-
tation nor PI3K pathway alteration by mutations in
other pathway members were predictive of everolimus
benefit [38]. Interestingly, results from the TAMRAD
study suggest that mTOR activation by the LKB1/AMPK
pathway predicts everolimus efficacy [32].
Finally, research efforts should focus on patients with
primary or acquired resistance to mTOR inhibition.
Some markers of intrinsic resistance have already been
proposed in preclinical models, such as KRAS mutations
or a high 4EBP1/elF4E expression ratio [39,40].
Next-generation sequencing from the BOLERO-2 trial
has demonstrated that patients with a minimal number
of genetic alterations derived the greatest benefit from
everolimus, suggesting that concomitant mutations in
other oncogenic pathways might mediate resistance or
attenuate everolimus efficacy [38]. Interestingly, this
study found that FGFR1 amplification was associated
with reduced sensitivity to mTOR inhibitors.
Everolimus sensitivityHigh sensitivity Intrinsic
resistance
4EBP1/ eIF4E expression 
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Figure 3 Everolimus sensitivity. Schematic representation of the sensitivity to everolimus. 4E-BP1, eIF4E binding protein 1; AKT, protein kinase
B; AMPK, adenosine monophosphate-activated protein kinase; IGF1R, insulin growth factor 1-receptor; LKB1, liver kinase B1; mTOR, mammalian tar-
get of rapamycine; PI3K, phosphatidylinositol-3-kinase.
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activating feedback loops involving insulin growth factor
1-receptor (IGF-1R)/PI3K can occur during mTOR
inhibition, resulting in AKT and mitogen-activated
protein kinase activation [41,42] (Figure 4). These
observations suggest that multiple drug combinations may









Figure 4 Feedback loops after rapalog exposure. After rapamycin, vario
(S6K1). The S6K1/insulin-like growth factor 1 receptor (IGF-1R)/phosphatidy
while the second loop is S6K1/IGF-IR/PI3K and mitogen-activated protein
secondary resistance to mammalian target of rapamycin (mTOR) inhibito
TK, tyrosine kinase.temsirolimus and cituxumumab, a fully human immu-
noglobulin G1 monoclonal antibody directed against IGF-1R,
was evaluated in a phase I trial [43]. Forty-two advanced
breast cancer patients were enrolled, including nine breast
cancer patients. Four of the nine presented a stable disease
for 1 to 5 months. Other trials testing rapalogs plus IGF-1R









us feedback loops are triggered by ribosomal protein S6 kinase beta-1
linositol-3-kinase (PI3K) loop results in protein kinase B (AKT) activation,
kinase (MAPK) pathway-dependent. Both loops are implicated in
rs. mTORC, mTOR complex; P, phosphorylated; Ras, rat sarcoma virus;
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responsible mechanisms in patients, it may be possible to de-
sign personalized approaches to restore mTOR inhibition
sensitivity. Another strategy may be to use ATP competitive
mTORC1 and mTORC2 inhibitors, which may result in
both stronger mTOR inhibition (as defined by higher bio-
activity on p4EBP1) and in the blockade of the potential
feedback loop that involves mTORC2 [44]. Interestingly, a
phase 1 trial with a dual mTORC1/mTORC2 inhibitor
(INK128) enrolled 52 patients with advanced cancers
treated according to three schedules. The authors recently
presented their findings: toxicities were dependent on the
protocol and were acceptable and the primary results on
anti-tumor activity are interesting [45]. Moreover, a phase
1 trial of oral PI3K/mTOR inhibitor P7170 in patients with
advanced refractory solid tumors is ongoing (ClinicalTrials.
gov number NCT01762410) and this combination is going
to be tested in patients with advanced breast cancer with
exemestane in a phase 2 trial (ClinicalTrials.gov number
NCT01658176). These results will be highly anticipated.
Conclusion
In this review we have highlighted the importance of in-
tegrating biologic and clinical data for the clinical deve-
lopment of mTOR inhibitors. Indeed, a molecular
stratification of breast cancer patients based on mTOR-
related factors may be key for future research in the
field. Overall, various ongoing phase III clinical trials are
testing the efficacy of everolimus according to the hy-
pothesized timing of mTOR activation, for both HR +
and HER2+ breast cancer. This reflects the proposed
classification into ‘baseline’ and ‘during treatment’
mTOR activation. Furthermore, biomarker studies in
the metastatic setting and new tools for molecular
diagnosis (such as phosphoprotein quantification and
polysome profiling) should be conducted and deve-
loped in the proposed patients groups. These will help
answer some of the major unanswered questions. In
addition, studies in the post-everolimus setting will be
required for the second wave of rapalogs.Note: This article is part of a series on “Recent advances in
breast cancer treatment”, edited by Jenny Chang. Other
articles in this series can be found at http://breast-cancer-
research.com/series/treatment.Abbreviations
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